What once was a mere rumor is now a legitimate possibility: the Apple Watch may be getting glucose monitoring features by 2022.
It has been revealed that a Securities and Exchange Commission (SEC) filing for Rockley Photonics, a UK-based developer of silicon photonics, has quite a notable connection to the tech giant Apple. It is believed that this relationship between the two companies further implies the likeliness of Apple adding a blood sugar monitoring feature to the Apple Watch by next year, 2022.
Among the innovations it is known for, Rockley Photonics produces sensors that are designed to monitor a person’s blood by utilizing infrared light technology. These sensors are created with the ability to monitor elements that most medical and other specialized equipment are capable of tracking, such as alcohol and blood glucose levels.
Is Apple among Rockley’s major clients?
According to Apple Insider, there is an SEC filing (reported first by The Daily Telegraph, UK) detailing that Rockley Photonics is currently in the preparation process of going public in New York, disclosing information on its affiliations in terms of finance as well. The text then goes on to specify that one of Rockley’s “few large customers” so happens to be Apple.
As per Rockley’s claims, 99.6% of its 2019 revenue and 100% of its 2020 revenue was accounted for by two of the largest customers on its books. Although there have been no direct mentions of Apple being either of the firm’s two largest clients, considering the tech giant’s focus on product improvement, its interest in sensors, as well as the fact it was named in the document at all, it is very probable that Apple is indeed among the startup’s most significant clients.
There is talk about a “supply and development agreement” presently going on between Apple and Rockley Photonics; it is believed that the startup continuously relies on Apple’s role in the deal for a large part of its income. A good amount of Rockley’s profits come from engineering fees for a number of future products’ development work as well.
Andrew Rickman, CEO of Rockley Photonics, stated that he expects the company’s developed technologies to make their way into consumer products by 2022, next year. He said nothing, however, about the firm having any involvement with Apple.
The rumors surrounding Apple’s plans to incorporate glucose monitoring into its Apple Watches have been going around for quite some time. In fact, further gossip on the “Apple Watch Series 7” claims that customers don’t have too much longer to wait until the feature officially shows up on the tech giant’s reputable gadgets. Moreover, Apple has been occupied with component patent applications that may be produced to monitor glucose levels through skin alone without any need for blood drawing.
Though the credibility of this speculation may not be confirmed, this reliable news may be enough for some to hold off on getting one of the Apple Watches already available on the market just in case any of the coming models will indeed sport this new feature. Those who find no need for such a monitor and would rather not postpone their next purchase will probably be content with an Apple Watch Series 3 or Apple Watch Series 6.